Drugs / DXC008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06926283 | May 2025 → Apr 2030 expected | Ewing sarcoma, prostate cancer | Hangzhou DAC Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DXC008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06926283 ↗ |